Abstract: The invention relates to a life vest container device, in particular aircraft seat life vest container device, for a life vest unit, with a life vest container comprising an accommodation unit that has an accommodation space as well as an access opening to the accommodation space, and with a monitoring device. It is proposed that the monitoring device is at least configured to capture a change of at least one characteristic via at least one electric and/or electronic signal.

Abstract: A life vest device, for a fixation on one or more aircraft seats, with a life vest unit, which is embodied as a lift vest with a packaging unit for a sealed accommodation of the life vest unit and with an opening unit for an opening of the packaging unit, which features one or more pull straps. The opening unit is functionally connected with the life vest unit and the packaging unit comprises one or more fixation units for a fixation on an aircraft seat. For a retrieval of the life vest unit from the packaging unit, the opening unit is connected in a tear-proof manner with the life vest unit. The pull strap and the life vest are embodied integrally with each other.

Abstract: The invention relates to a life vest device, in particular for a fixation on at least one aircraft seat, with at least one life vest unit, with at least one packaging unit for an, in particular sealed, accommodation of the at least one life vest unit and with at least one opening unit for an opening of the at least one packaging unit. It is proposed that the at least one opening unit is functionally connected with the at least one life vest unit and that the at least one packaging unit comprises at least one fixation unit for a fixation on an aircraft seat.

Abstract: The invention relates to a life vest container device, in particular aircraft seat life vest container device, for a life vest unit, with a life vest container comprising an accommodation unit that has an accommodation space as well as an access opening to the accommodation space, and with a monitoring device. It is proposed that the monitoring device is at least configured to capture a change of at least one characteristic via at least one electric and/or electronic signal.

Abstract: An aircraft seat device includes at least one seat bottom unit, a mounting unit, and at least one carrier element. The at least one seat bottom unit at least partly implements a seat surface. The at least one carrier element couples the seat bottom unit with the mounting unit and transfers force from the seat bottom unit to the mounting unit.

Abstract: An aircraft seat device includes at least one seat bottom unit, which at least partly implements a seat surface and includes a mounting unit, which is configured to be mounted on a mounting plane, and includes at least one carrier element, which extends at least over a large portion of a seat depth of the seat surface and is configured for coupling the seat bottom unit with the mounting unit.

Abstract: The present invention relates in fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or arterial flutter.

Abstract: The present invention relates in fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

Abstract: The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or arterial flutter.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

Abstract: The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

Abstract: The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

Abstract: KCNQ5, DNA encoding KCNQ5 or a polypeptide having KCNQ5 activity, related vectors, host cells and methods and a screening assay for identification of compounds which modify activity of a potassium channel KCNQ5 are described.

Abstract: KCNQ5, DNA encoding KCNQ5 or a polypeptide having KCNQ5 activity, related vectors, host cells and methods and a screening assay for identification of compounds which modify activity of a potassium channel KCNQ5 are described.